## Florida Senate - 2002

## CS for CS for CS for SB 636

**By** the Committees on Appropriations; Judiciary; Health, Aging and Long-Term Care; and Senator Burt

ĺ	309-2025-02
1	A bill to be entitled
2	An act relating to controlled substances;
3	providing for specified licensing boards to
4	adopt rules governing the prescribing of
5	controlled substances; requiring certain health
6	care providers to complete education courses
7	relating to the prescription of controlled
8	substances; providing penalties and requiring a
9	report; providing for the emergency suspension
10	of certain licenses for prescribing violations;
11	requiring the Department of Health, the
12	Department of Law Enforcement, the Statewide
13	Prosecutor, and State Attorneys to share
14	certain information regarding health care
15	practitioners; requiring a report; requiring
16	the Department of Legal Affairs to establish an
17	electronic system to monitor the prescribing of
18	certain controlled substances; establishing an
19	advisory council and providing for its
20	membership, duties, staff, and compensation;
21	amending s. 456.033, F.S.; eliminating certain
22	requirements for HIV and AIDS education
23	courses; amending s. 456.072, F.S., revising
24	penalties; amending s. 458.345, F.S.; requiring
25	certain resident physicians, interns, and
26	fellows to complete an educational course in
27	prescribing controlled substances; amending s.
28	461.013, F.S.; prohibiting the presigning of
29	blank prescription forms and providing
30	penalties; amending s. 893.04, F.S.; providing
31	additional requirements for pharmacists

1

1	regarding the identification of persons to whom
2	controlled substances are dispensed;
3	prohibiting certain prescribing practitioners
4	from possessing, administering, dispensing, or
5	prescribing controlled substances; providing an
6	effective date.
7	
8	Be It Enacted by the Legislature of the State of Florida:
9	
10	Section 1. Physicians; rules establishing prescribing
11	guidelinesTo minimize the diversion and resultant abuse of
12	controlled substances, the Board of Medicine and the Board of
13	Osteopathic Medicine shall adopt rules to establish guidelines
14	for prescribing controlled substances to patients in
15	emergency-department settings. Such guidelines must allow
16	physicians to provide legitimate medical treatment of acute
17	and chronic pain and require them to recognize and prevent
18	abuse of pain medications prescribed in emergency-department
19	settings. The guidelines must also consider requirements of
20	state and federal law and of the Joint Commission on the
21	Accreditation of Healthcare Organizations. Each board shall
22	consult with the Florida College of Emergency Physicians in
23	developing these guidelines.
24	Section 2. Instruction required for certain licensees
25	in prescribing and pharmacology
26	(1) The appropriate professional licensing board shall
27	require each person licensed under chapter 458, chapter 459,
28	chapter 461, chapter 462, or chapter 466, Florida Statutes, to
29	complete a 1-hour educational course, approved by the board,
30	on appropriate prescribing and pharmacology of controlled
31	substances, as part of the licensee's initial license renewal
	2

2

1 after January 1, 2003. The course shall provide education in the state and federal laws and rules governing the prescribing 2 3 and dispensing of controlled substances; in appropriate evaluation of patients for any risk of drug diversion and the 4 5 resulting abuse of controlled substances; in the use of б informed consent and other protocols, such as discussing the risks and benefits of using controlled substances, with 7 8 patients to prevent drug diversion; in the need to keep accurate and complete medical records to justify treatment 9 10 with controlled substances; in addiction and substance-abuse 11 issues with respect to patients; in the appropriate use of recognized pain-management guidelines; and in the need for 12 consultation and referral of patients who are at risk for 13 misuse of medication or diversion of controlled substances, 14 15 when appropriate. The board may approve additional equivalent 16 (2) 17 courses that satisfy the requirements of subsection (1). Each licensing board that requires a licensee to complete an 18 19 educational course pursuant to this section shall include the hours required to complete the course in the total required 20 continuing educational requirements. 21 (3) Any person who holds two or more licenses subject 22 to this section may satisfy the requirements of this section 23 24 by taking only one such board-approved course for relicensure 25 of all such licenses. (4) A licensee who fails to comply with this section 26 27 is subject to disciplinary action under each respective 28 practice act and section 456.072(1)(k), Florida Statutes. In 29 addition to discipline by the board, the licensee must 30 complete the course. 31

1 (5) The board shall require, as a condition of granting a license under the chapter specified in subsection 2 3 (1), that an applicant for initial licensure complete an educational course set forth in subsection (1). An applicant 4 5 who has not taken a course at the time of licensure shall be б allowed 6 months within which to complete this requirement. The board may adopt rules necessary to administer 7 (6) 8 this section. 9 Section 3. Emergency suspension orders; controlled 10 substances.--Upon receipt of sufficient evidence from any 11 agency authorized to enforce chapter 893, Florida Statutes, regarding a violation of section 458.331(1)(q), section 12 458.331(1)(r), section 458.331(1)(aa), section 459.015(1)(t), 13 14 section 459.015(1)(u), section 459.015(1)(ee), section 461.013(1)(0), section 461.013(1)(p), section 461.013(1)(dd), 15 section 462.14(1)(q), section 462.14(1)(r), section 16 17 462.14(1)(aa), section 464.018(1)(i), section 465.016(1)(e), section 465.016(1)(i), section 466.028(1)(p), section 18 19 466.028(1)(q), section 466.028(1)(r), or section 466.028(1)(dd) or of chapter 893, Florida Statutes, by a 20 licensed health care practitioner who is authorized to 21 prescribe, dispense, or administer controlled substances, the 22 Department of Health shall review the case and if the 23 24 practitioner is a danger to the public health, safety, or 25 welfare of the public as set forth in section 120.60(6), Florida Statutes, recommend the suspension or restriction of 26 27 the practitioner's license to the Secretary of Health within 10 working days after receiving such evidence. The Secretary 28 29 of Health may suspend or restrict the license of the practitioner in accordance with section 120.60(6), Florida 30 31 Statutes.

4

1	Section 4. Sharing of arrest, formal-charging, and
2	other information regarding health care practitioners
3	(1) In order to facilitate the efficiency of the
4	Department of Health's investigation of applicable violations
5	involving the diversion of controlled substances by such
6	practitioners, or other violations of criminal law that may
7	adversely affect a practitioner's licensed practice, any law
8	enforcement agency that arrests a person known or suspected to
9	be a health care practitioner licensed by the state shall
10	promptly notify the Department of Health and provide it with:
11	(a) Notice of the arrest, including the name of the
12	arresting agency and lead investigator, detective, or officer
13	in the case;
14	(b) The name of the person charged;
15	(c) All known personal identifying information related
16	to the person arrested;
17	(d) The date of the arrest;
18	(e) The charges for which the person is arrested;
19	(f) The agency case number assigned to the arrest; and
20	(g) The arrest report, investigative report, or
21	statement of the allegations supporting the arrest.
22	(2) A state attorney or the Statewide Prosecutor, upon
23	the filing of an indictment or information against a person
24	known or suspected to be a health care practitioner licensed
25	by the state, shall forward a copy of the indictment or
26	information to the Department of Health.
27	(3) The Medical Examiners Commission within the
28	Department of Law Enforcement shall report to the Department
29	of Health quarterly any information in its possession
30	regarding the deaths of persons who had lethal levels of
31	controlled substances in their bodies as such information has
	5

**Florida Senate - 2002** 309-2025-02

1 been reported to the commission by the medical examiners 2 within the state. 3 (4) Upon receipt of arrest information from a law enforcement agency or notice of formal charging by a 4 5 prosecuting entity, the Department of Health or the board б having regulatory authority over the practitioner shall 7 investigate any information received and determine whether it 8 has reasonable grounds to believe that the practitioner has violated any law relating to the practitioner's practice and 9 10 shall take appropriate licensure action as provided by law or 11 rule. If the Department of Health receives information pursuant to this section which suggests that the person 12 arrested or charged is also licensed by the state in another 13 field or profession, the Department of Health shall forward 14 such information to the appropriate licensing entity for 15 review and appropriate licensure action as provided by law or 16 17 rule. To help the Department of Health and regulatory (5) 18 19 boards control the diversion and resultant abuse of controlled substances, the Department of Health and the Department of Law 20 Enforcement shall study the feasibility of expanding the 21 electronic exchange of information to facilitate the transfer 22 to the Department of Health of criminal-history information 23 24 involving licensed health care practitioners who are 25 authorized to prescribe, administer, or dispense controlled substances. The study must address whether the collection and 26 27 retention of fingerprint information concerning licensed 28 health care practitioners subject to the profiling provisions 29 of sections 456.039 and 456.0391, Florida Statutes, is advisable as a means of better regulating such practitioners 30 and guarding against abuse of the privileges of such licensure 31

б

1 with respect to controlling the diversion and resultant abuse of controlled substances. The Department of Law Enforcement 2 3 shall investigate the feasibility of the electronic transmission of information from medical examiners within this 4 5 state to the Department of Health regarding autopsies and б other public reports that attribute death to 7 controlled-substance abuse. The Department of Law Enforcement, 8 in consultation with the Department of Health, must submit a report of its findings to the Legislature by November 1, 2002. 9 10 Section 5. Electronic monitoring system for 11 prescriptions.--(1) By July 1, 2003, the Department of Legal Affairs 12 shall design and establish an electronic system consistent 13 with the National Council of Prescription Drug Programs 14 (NCPDP) standards or the American Society for Automation in 15 Pharmacy (ASAP) standards to monitor the prescribing of 16 Schedule II controlled substances, other drugs designated by 17 rule by the Attorney General under this section, and codeine, 18 19 hydrocodone, dihydrocodeine, ethylmorphine, and morphine, as scheduled in Schedule II and Schedule III, by health care 20 practitioners within the state or the dispensing of such 21 controlled substances to an address within the state by a 22 pharmacy permitted or registered by the Board of Pharmacy. 23 24 (2) All Schedule II controlled substances, and codeine hydrocodone, dihydrocodeine, ethylmorphine, and morphine as 25 26 scheduled in Schedule II and Schedule III, and any other drug 27 designated by the Attorney General under this section shall be included in the electronic monitoring system. The Attorney 28 29 General may, by rule, designate any other drug for inclusion 30 in such system after making a determination that the drug is a 31 drug of abuse. The Attorney General must consider the 7

1 recommendations of the prescription-monitoring advisory council created by this section before designating a drug of 2 3 abuse for inclusion in the electronic monitoring system and 4 only after he or she determines that the current level of 5 regulation over the prescribing and dispensing of such drug is б inadequate and that the drug has a high potential for abuse or 7 is being excessively misused, abused, or diverted into illicit 8 drug trafficking. 9 (3) Each controlled substance or drug subject to this 10 section which is dispensed in this state must be timely 11 reported to the Department of Legal Affairs. Such data must be 12 reported each time that: 13 (a) A Schedule II controlled substance is dispensed; 14 (b) A drug that is designated by the Attorney General 15 under subsection (2) is dispensed; or (c) Codeine, hydrocodone, dihydrocodeine, 16 17 ethylmorphine, or morphine as scheduled in Schedule II and Schedule III is dispensed. 18 19 (4) This section does not apply to controlled 20 substances or drugs: (a) Ordered from an institutional pharmacy licensed 21 under section 465.019(2), Florida Statutes, in accordance with 22 the institutional policy for such controlled substances or 23 24 drugs; or 25 (b) Administered by a health care practitioner to a 26 patient or resident receiving care from a hospital, nursing 27 home, assisted living facility, home health agency, hospice, 28 or intermediate care facility for the developmentally disabled 29 which is licensed in this state. The data required under this section includes: 30 (5) 31 The patient's name. (a)

8

**Florida Senate - 2002** 309-2025-02

1 (b) The patient's address. 2 (C) The national drug code number of the substance 3 dispensed. 4 (d) The date that the substance is dispensed. 5 The quantity of substance dispensed. (e) б (f) The dispenser's National Association of Board's of 7 Pharmacy (NABP) number. 8 The prescribing practitioner's United States Drug (q) 9 Enforcement Administration Number. (6) 10 The information must be reported within 30 days 11 after the date the controlled substance or drug is dispensed. (7) A dispenser must transmit the information required 12 by this section in an electronic format approved by rule of 13 the Board of Pharmacy after consultation with the advisory 14 council and the Department of Legal Affairs unless a specific 15 waiver is granted to that dispenser by the Department of Legal 16 17 Affairs. The Department of Legal Affairs shall establish a 18 (8) 19 13-member prescription-monitoring program advisory council to assist it in identifying drugs of abuse for inclusion in the 20 21 monitoring system and in implementing the system. The Governor shall appoint members to serve on the 22 (a) advisory council. The members of the council shall include the 23 24 Attorney General or his or her designee who shall serve as the 25 chairperson; the Secretary of Health or his or her designee; the executive director of the Department of Law Enforcement or 26 27 his or her designee; the director of the Office of Drug Control within the Executive Office of Governor or his or her 28 29 designee; a physician who is licensed in this state under 30 chapter 458, Florida Statutes, who is recommended by the Florida Medical Association; a physician who is licensed in 31

9

1 this state under chapter 459, Florida Statutes, who is recommended by the Florida Osteopathic Medical Association; a 2 3 podiatric physician who is licensed in this state under chapter 461, Florida Statutes, who is recommended by the 4 5 Florida Podiatric Medical Association; a pharmacist who is б licensed in this state under chapter 465, Florida Statutes, who is recommended by the Florida Pharmacy Association; a 7 8 pharmacist who is licensed in this state under chapter 465, Florida Statutes, who is recommended by the Florida Retail 9 Federation; a pharmacist who is licensed in this state under 10 11 chapter 465, Florida Statutes, who is recommended by the National Community Pharmacy Association; a dentist who is 12 licensed in this state under chapter 466, Florida Statutes, 13 who is recommended by the Florida Dental Association; a 14 15 veterinarian who is licensed in this state under chapter 474, Florida Statutes, who is recommended by the Florida Veterinary 16 17 Medical Association; and a prosecutor who has expertise in the criminal prosecution of drug-diversion cases. 18 19 (b) The advisory council members shall meet no more often than quarterly at the call of the chairperson, and serve 20 without compensation. However, such members may receive 21 reimbursement, as provided in section 112.061, Florida 22 Statutes, for per diem and travel expenses incurred in the 23 24 performance of their official duties. 25 (c) The Department of Legal Affairs shall provide staff and other administrative assistance that is reasonably 26 27 necessary to assist the advisory council in carrying out its 28 responsibilities. The Department of Legal Affairs shall adopt rules 29 (9) pursuant to section 120.536(1) and section 120.574, Florida 30 31 Statutes, necessary to administer this section.

10

1 Section 6. Subsections (1) and (9) of section 456.033, Florida Statutes, are amended to read: 2 3 456.033 Requirement for instruction for certain licensees on HIV and AIDS.--4 5 (1) The appropriate board shall require each person б licensed or certified under chapter 457; chapter 458; chapter 7 459; chapter 460; chapter 461; chapter 463; part I of chapter 8 464; chapter 465; chapter 466; part II, part III, part V, or 9 part X of chapter 468; or chapter 486 to complete a continuing 10 educational course, approved by the board, on human 11 immunodeficiency virus and acquired immune deficiency syndrome as part of biennial relicensure or recertification. The course 12 shall consist of education on the modes of transmission, 13 infection control procedures, clinical management, and 14 prevention of human immunodeficiency virus and acquired immune 15 deficiency syndrome. Such course shall include information on 16 17 current Florida law on acquired immune deficiency syndrome and its impact on testing, confidentiality of test results, 18 19 treatment of patients, and any protocols and procedures 20 applicable to human immunodeficiency virus counseling and testing, reporting, the offering of HIV testing to pregnant 21 women, and partner notification issues pursuant to ss. 381.004 22 23 and 384.25. 24 (9)(a) In lieu of completing a course as required in 25 subsection (1), the licensee may complete a course in 26 end-of-life care and palliative health care, so long as the 27 licensee completed an approved AIDS/HIV course in the 28 immediately preceding biennium. 29 (b) In lieu of completing a course as required by 30 subsection (1), a person licensed under chapter 466 who has 31 completed an approved AIDS/HIV course in the immediately 11

**Florida Senate - 2002** 309-2025-02

1 preceding 2 years may complete a course approved by the Board 2 of Dentistry. 3 Section 7. Paragraph (d) of subsection (2) of section 456.072, Florida Statutes, is amended to read: 4 5 456.072 Grounds for discipline; penalties; б enforcement. --7 (2) When the board, or the department when there is no 8 board, finds any person guilty of the grounds set forth in 9 subsection (1) or of any grounds set forth in the applicable 10 practice act, including conduct constituting a substantial 11 violation of subsection (1) or a violation of the applicable practice act which occurred prior to obtaining a license, it 12 13 may enter an order imposing one or more of the following penalties: 14 Imposition of an administrative fine not to exceed 15 (d) \$25,00016 17 violation is for fraud or making a false or fraudulent representation, the board, or the department if there is no 18 19 board, must impose a fine of \$10,000 per count or offense. 20 Section 8. Paragraph (d) is added to subsection (1) of 21 section 458.345, Florida Statutes, to read: 458.345 Registration of resident physicians, interns, 22 and fellows; list of hospital employees; prescribing of 23 24 medicinal drugs; penalty .--25 (1) Any person desiring to practice as a resident physician, assistant resident physician, house physician, 26 27 intern, or fellow in fellowship training which leads to 28 subspecialty board certification in this state, or any person 29 desiring to practice as a resident physician, assistant resident physician, house physician, intern, or fellow in 30 31 fellowship training in a teaching hospital in this state as 12

1 defined in s. 408.07(44) or s. 395.805(2), who does not hold a 2 valid, active license issued under this chapter shall apply to 3 the department to be registered and shall remit a fee not to 4 exceed \$300 as set by the board. The department shall 5 register any applicant the board certifies has met the б following requirements: 7 (d) Has completed, upon initial registration, the 8 1-hour educational course in the prescribing of controlled 9 substances as set forth in section 2 of this act. An applicant 10 who has not taken a course at the time of registration shall 11 be allowed up to 6 months within which to complete this 12 requirement. Section 9. Paragraph (dd) is added to subsection (1) 13 of section 461.013, Florida Statutes, to read: 14 15 461.013 Grounds for disciplinary action; action by the board; investigations by department. --16 17 (1) The following acts constitute grounds for denial 18 of a license or disciplinary action, as specified in s. 19 456.072(2): 20 (dd) Presigning blank prescription forms. Section 10. Paragraphs (h), (i), (j), (k), and (l) are 21 added to subsection (1) of section 893.04, Florida Statutes, 22 to read: 23 24 893.04 Pharmacist and practitioner.--25 (1) A pharmacist, in good faith and in the course of professional practice only, may dispense controlled substances 26 27 upon a written or oral prescription of a practitioner, under 28 the following conditions: 29 (h) A pharmacist may not dispense a Schedule II 30 controlled substance; codeine, hydrocodone, dihydrocodeine, 31 ethylmorphine, or morphine, as scheduled in Schedule II and 13

Schedule III; or a drug of abuse designated by the Attorney 1 General by rule under the prescription-monitoring system to 2 3 any individual not personally known to the pharmacist without 4 first obtaining suitable identification and documenting, in a 5 log book kept by the pharmacist, the identity of the б individual obtaining the controlled substance. The log book 7 entry must contain the printed name, address, telephone number 8 if available, and driver's license number or other suitable identification number, and signature of the person obtaining 9 the controlled substance or drug. If the individual does not 10 11 have suitable identification or it is impracticable to obtain such identification, the pharmacist may dispense the 12 controlled substance or drug only when the pharmacist 13 determines, in the exercise of her or his professional 14 judgment, that the order is valid and necessary for treatment. 15 In such a case, the pharmacist or his or her designee must 16 17 obtain the other information required under this paragraph, and the pharmacist or pharmacist's designee must sign the log 18 19 to indicate that suitable identification was not available and that the pharmacist's professional judgment was exercised 20 prior to dispensing the controlled substance or drug. The 21 Board of Pharmacy may adopt, by rule, procedures for a 22 pharmacist to verify the validity of a prescription for a 23 24 Schedule II controlled substance; other drug designated by the 25 Attorney General under this section; or codeine, hydrocodone, dihydrocodeine, ethylmorphine, or morphine, as scheduled in 26 27 Schedule II and Schedule III, for circumstances when it is 28 otherwise impracticable for the pharmacist or dispensing 29 practitioner to obtain suitable identification from the patient or the patient's agent. For purposes of this section, 30 identification is suitable only if it contains the photograph, 31

14

1 the printed name, and the signature of the individual obtaining the Schedule II controlled substance or drug of 2 3 abuse under the prescription-monitoring system. 4 (i) Any pharmacist that dispenses a Schedule II 5 controlled substance or drug subject to the requirements of б this section when dispensed by mail shall be exempt from the 7 requirements to obtain suitable identification. 8 (j) All prescriptions issued for a Schedule II 9 controlled substance; codeine, hydrocodone, dihydrocodeine, 10 ethylmorphine, or morphine, as scheduled in Schedule II and 11 Schedule III; or a drug of abuse under the prescription-monitoring system which has been designated by 12 the Attorney General by rule, must include both a written and 13 14 numerical notation of quantity on the face of the 15 prescription. (k) A pharmacist may not dispense more than a 30-day 16 17 supply of a controlled substance listed in Schedule III upon an oral prescription. 18 19 (1) A pharmacist may not knowingly fill a prescription that has been mutilated or forged for a Schedule II controlled 20 21 substance; codeine, hydrocodone, dihydrocodeine, 22 ethylmorphine, and morphine, as scheduled in Schedule II and Schedule III; or a drug of abuse under the 23 24 prescription-monitoring system which has been designated by 25 the Attorney General by rule. Section 11. This act shall take effect July 1, 2002. 26 27 28 29 30 31

STATEMENT OF SUBSTANTIAL CHANGES CONTAINED IN COMMITTEE SUBSTITUTE FOR CS/CS/SB 636 Eliminates requirement to investigate all reports of overdose deaths. Inserts clarification that the study addresses only health care practitioners subject to the profiling provisions of ss. 456.039 & 456.0391,F.S. б Allows a pharmacist to dispense the controlled substance in the absence of "suitable identification" if, in the professional judgment of the pharmacist the order is valid and necessary for treatment. Deletes requirement that the Department of Legal Affairs develop a counterfeit-proof prescription form to be used by practitioners who prescribe controlled substances. Also deletes proposed processes that must be followed prior to dispensing controlled substances. Directs law enforcement agencies to provide to the Department of Health reports and statements of the allegations supporting the arrest of health care practitioners.